Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | ACHE | P22303 | 8/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | ADH1B | P00325 | 1/20 | 0.32 |
| ▸ | ADH1C | P00326 | 1/20 | 0.32 |
| ▸ | ADH1A | P07327 | 1/20 | 0.32 |
| ▸ | ADH7 | P40394 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2833761 | 1.00 | CNR2 (0.36) | CNR2ACHECNR1EPHX1ALOX15 | |
| SCHEMBL28878340 | 0.89 | CNR2 (0.31) | CNR2 | |
| SCHEMBL27625148 | 0.82 | — | — | |
| SCHEMBL1486752 | 0.81 | — | — | |
| SCHEMBL27620783 | 0.80 | ACHE (0.45) | CNR2ACHECNR1EPHX1ALOX15 | |
| SCHEMBL27921568 | 0.80 | LMNA (0.34) | ALOX15ALDH1A1 | |
| SCHEMBL1997169 | 0.76 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL1997173 | 0.76 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL27999662 | 0.76 | ACHE (0.49) | ACHEEPHX1 | |
| SCHEMBL4609619 | 0.76 | TSHR (0.48) | CNR2ACHEEPHX1ALOX15MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055280-A1 | RADIATION SENSITIVE COMPOSITIONS COMPRISING A COMBINATION OF METALS OR METALLOID COMPOUNDS | ISP INVESTMENTS LLC (US) | 2026-02-26 | — | — | US | disclosed |
| EP-4416552-A1 | RADIATION SENSITIVE COMPOSITIONS COMPRISING A COMBINATION OF METALS OR METALLOID COMPOUNDS | ISP Investments LLC (US) | 2024-08-21 | — | — | EP | disclosed |
| WO-2023211667-A1 | MULTILAYER RADIOCHROMIC STRUCTURES AND USES THEREOF | ISP INVESTMENTS LLC (US) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023064136-A1 | RADIATION SENSITIVE COMPOSITIONS COMPRISING A COMBINATION OF METALS OR METALLOID COMPOUNDS | ISP INVESTMENTS LLC (US) | 2023-04-20 | — | — | WO | disclosed |
| US-7678381-B2 | Stabilized body care products, household products, textiles and fabrics | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2010-03-16 | — | — | US | disclosed |
| US-20070079446-A1 | Stabilized body care products, household products, textiles and fabrics | CIBA SPECIALTY CHEMICALS CORP. | 2007-04-12 | — | — | US | disclosed |
| EP-0338486-B1 | Stable emulsion polymers and methods of preparing same | JOHNSON & SON INC S C (US) | 1996-12-11 | — | — | EP | disclosed |
| EP-0338486-A2 | Stable emulsion polymers and methods of preparing same | S.C. JOHNSON & SON, INC. (US) | 1989-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070079446-A1 | Stabilized body care products, household products, textiles and fabrics | CUTA, NISCH, DSC1 | CNR2 3719/4885ACHE 2135/4885CNR1 4097/4885 |
| US-20260055280-A1 | RADIATION SENSITIVE COMPOSITIONS COMPRISING A COMBINATION OF METALS OR METALLOID COMPOUNDS | BRCA1, ATR, ATM | CNR2 4670/4885ACHE 439/4885CNR1 4535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.